keyword
MENU ▼
Read by QxMD icon Read
search

Her2 breast cancer

keyword
https://www.readbyqxmd.com/read/29474991/endocrine-therapy-and-palbociclib-within-a-compassionate-use-program-in-heavily-pretreated-hormone-receptor-positive-her2-negative-metastatic-breast-cancer
#1
Christian Maurer, Arlindo R Ferreira, Samuel Martel, Matteo Lambertini, Noam Pondé, Philippe Aftimos, Evandro de Azambuja, Martine Piccart
This is a single center retrospective analysis of patients with hormone receptor-positive, HER2-negative metastatic breast cancer progressing after ≥ 4 treatment lines treated with palbociclib in combination with endocrine therapy within a compassionate use program. Thirty-four patients were included between 10/2015 and 02/2017, the majority (82.4%) being previously treated with mTOR inhibitors. Disease control rate was 52.9% and 24.4% at week 12 and 24. Overall progression-free survival was 3.1 months with no difference between mTOR inhibitor-pretreated (3...
February 20, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29473333/risk-factors-and-survival-outcomes-in-patients-with-breast-cancer-and-lung-metastasis-a-population-based-study
#2
Weikai Xiao, Shaoquan Zheng, Peng Liu, Yutian Zou, Xinhua Xie, Ping Yu, Hailin Tang, Xiaoming Xie
The risk factors for morbidity and mortality in breast cancer lung metastases (BCLM) patients still remain poorly identified. The aim of this study was to assess the incidence and survival of BCLM and associated risk factors. Patients with BCLM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate logistic regression analysis was used to determine the risk factors for BCLM. Predictors of factors associated with death were analyzed in Cox regression and Fine and Gray's test...
February 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29471794/lgr5-overexpression-confers-poor-relapse-free-survival-in-breast-cancer-patients
#3
Ming-Feng Hou, Po-Ming Chen, Pei-Yi Chu
BACKGROUND: Cancer stem cells (CSCs) are believed to promote the malignant transformation of breast cancer via multiple signaling pathways, including the Wnt/β-catenin pathway. Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) has been identified as a CSC-associated Wnt-regulated target gene, but its clinical significance in the context of breast cancer remains elusive. Therefore, the purpose of this study was to investigate the clinical significance of the LGR5-β-catenin axis in breast cancer...
February 22, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29471435/immune-infiltration-in-invasive-lobular-breast-cancer
#4
Christine Desmedt, Roberto Salgado, Marco Fornili, Giancarlo Pruneri, Gert Van den Eynden, Gabriele Zoppoli, Françoise Rothé, Laurence Buisseret, Soizic Garaud, Karen Willard-Gallo, David Brown, Yacine Bareche, Ghizlane Rouas, Christine Galant, François Bertucci, Sherene Loi, Giuseppe Viale, Angelo Di Leo, Andrew R Green, Ian O Ellis, Emad A Rakha, Denis Larsimont, Elia Biganzoli, Christos Sotiriou
Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. Methods: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC)...
February 20, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29471352/delay-to-formalin-fixation-cold-ischemia-time-effect-on-breast-cancer-molecules
#5
Thaer Khoury
Objectives: The gold standard of examining breast biomarkers, including estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)/Ki-67, is to perform these assays on formalin-fixed, paraffin-embedded tissue. However, preanalytical variables may confound these assays. One of these factors is delay to formalin fixation (DFF). The purpose of this review is to evaluate each study that investigated the effect of DFF on breast biomarkers and other molecules...
February 19, 2018: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29471066/a-pharmacokinetic-study-on-lapatinib-in-type-2-diabetic-rats
#6
Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Agnieszka Klupczynska, Szymon Plewa, Tomasz Grabowski, Anna Wolc, Marta Moch, Zenon J Kokot, Edmund Grześkowiak
BACKGROUND: Diabetes mellitus (DM) is a complex metabolic disorder which affects the function of numerous tissues and alters the pharmacokinetic parameters of many drugs. As many oncological patients are diabetics, it is important to determine the influence of this chronic disease on the pharmacokinetics (PK) of anticancer drugs. Lapatinib is a tyrosine kinase inhibitor (TKI), approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer...
September 18, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29470143/tumor-pik3ca-genotype-and-prognosis-in-early-stage-breast-cancer-a-pooled-analysis-of-individual-patient-data
#7
Dimitrios Zardavas, Luc Te Marvelde, Roger L Milne, Debora Fumagalli, George Fountzilas, Vassiliki Kotoula, Evangelia Razis, George Papaxoinis, Heikki Joensuu, Mary Ellen Moynahan, Bryan T Hennessy, Ivan Bieche, Lao H Saal, Olle Stal, Barry Iacopetta, Jeanette Dupont Jensen, Sandra O'Toole, Elena Lopez-Knowles, Mattia Barbaraeschi, Shinzaburo Noguchi, Hatem A Azim, Enrique Lerma, Thomas Bachelot, Qing Wang, Gizeh Perez-Tenorio, Cornelis J H Can de Velde, Daniel W Rea, Vicky Sabine, John M S Bartlett, Christos Sotiriou, Stefan Michiels, Sherene Loi
Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study...
February 22, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29468485/characterization-of-a-novel-breast-cancer-cell-line-derived-from-a-metastatic-bone-lesion-of-a-breast-cancer-patient
#8
Julie Johnson, Darrell C Bessette, Jodi M Saunus, Chanel E Smart, Sarah Song, Rebecca L Johnston, Sibylle Cocciardi, Esdy N Rozali, Cameron N Johnstone, Ana Christina Vargas, Stephen H Kazakoff, Victorian Cancer BioBank, Kum Kum Khanna, Sunil R Lakhani, Georgia Chenevix-Trench, Peter T Simpson, Katia Nones, Nicola Waddell, Fares Al-Ejeh
PURPOSE: We aimed to generate and characterize a novel cell line from a breast cancer bone metastasis to better study the progression of the disease. METHODS: The cell line, P7731, was derived from a metastatic bone lesion of a breast cancer patient and assessed for marker expression. P7731 was analyzed for DNA copy number variation, somatic mutations, and gene expression and was compared with the primary tumor. RESULTS: P7731 cells are negative for estrogen receptor alpha (ERα), progesterone receptor (PR), and HER2 (triple-negative); strongly express vimentin (100% of cells positive) and also express cytokeratins 8/18 and 19 but at lower frequencies...
February 21, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29468454/randomized-phase-ii-study-of-anastrozole-plus-tegafur-uracil-as-neoadjuvant-therapy-for-er-positive-breast-cancer-in-postmenopausal-japanese-women-neo-acet-bc
#9
Takahiro Nakayama, Yasuaki Sagara, Tsutomu Takashima, Nobuki Matsunami, Norikazu Masuda, Yasuo Miyoshi, Tetsuya Taguchi, Toyokazu Aono, Toshikazu Ito, Tatsuo Kagimura, Shinzaburo Noguchi
PURPOSE: This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer. METHODS: Postmenopausal Japanese women with ER-positive, HER2-negative, T2,N0-1,M0 breast cancer seen at tertiary hospitals were eligible for this open-label, randomized, multicenter study. Patients were randomized 1:1 by minimization to orally receive either anastrozole (1 mg once daily) plus UFT (tegafur/uracil combination in 1:4 molar ratio; 270 mg/m2 /day in two divided doses) or anastrozole (as above) alone for 24 weeks...
February 21, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29467936/dynamic-changes-in-cd44v-positive-cells-after-preoperative-anti-her2-therapy-and-its-correlation-with-pathologic-complete-response-in-her2-positive-breast-cancer
#10
Teruo Yamauchi, Jose Rodrigo Espinosa Fernandez, Chiyo K Imamura, Hideko Yamauchi, Hiromitsu Jinno, Maiko Takahashi, Yuko Kitagawa, Seigo Nakamura, Bora Lim, Savitri Krishnamurthy, James M Reuben, Diane Liu, Debasish Tripathy, Helen Chen, Naoko Takebe, Hideyuki Saya, Naoto T Ueno
Chemotherapy has been reported to increase the proportion of cancer stem cells (CSCs) and to promote epithelial-mesenchymal transition (EMT) phenotype changes. Anti-HER2 therapy may provide a strategy for eliminating CSC and EMT, which contribute to therapeutic resistance. No study has determined the changes in the quantity or characteristics of CSCs or circulating tumor cells (CTCs) with EMT phenotype during preoperative anti-HER2 therapy, and whether these changes correlate to response to dual anti-HER2 therapy...
January 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29467583/bone-metastasis-pattern-in-initial-metastatic-breast-cancer-a-population-based-study
#11
Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
Purpose: Bone is one of the most common sites of breast cancer metastasis, and population-based studies of patients with bone metastasis in initial metastatic breast cancer (MBC) are lacking. Materials and methods: From 2010 to 2013, 245,707 breast cancer patients and 8901 patients diagnosed with initial bone metastasis were identified by Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Multivariate logistic and Cox regression were used to identify predictive factors for the presence of bone metastasis and prognosis factors...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29467582/neoadjuvant-chemotherapy-among-patients-treated-for-nonmetastatic-breast-cancer-in-a-population-with-a-high-hiv-prevalence-in-johannesburg-south-africa
#12
Paul Ruff, Herbert Cubasch, Maureen Joffe, Evan Rosenbaum, Nivashni Murugan, Ming-Chih Tsai, Oluwatosin Ayeni, Katherine D Crew, Judith S Jacobson, Alfred I Neugut
Background: Neoadjuvant (primary) chemotherapy (NACT) is the standard of care for locally advanced breast cancer. It also allows for the short-term assessment of chemotherapy response; a pathological complete responses correspond to improved long-term breast cancer outcomes. In sub-Saharan Africa, many patients are diagnosed with large nonresectable tumors. We examined NACT use in breast cancer patients who visited public hospitals in Johannesburg, South Africa. Methods: We assessed demographic characteristics, tumor stage and grade, hormone receptor status, and human immunodeficiency virus (HIV) status of female patients diagnosed with nonmetastatic invasive carcinoma of the breast at Chris Hani Baragwanath Academic Hospital between January 1, 2009, and December 31, 2011...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29467480/adenoid-cystic-carcinomas-of-the-salivary-gland-lacrimal-gland-and-breast-are-morphologically-and-genetically-similar-but-have-distinct-microrna-expression-profiles
#13
Simon Andreasen, Qihua Tan, Tina Klitmøller Agander, Petr Steiner, Kristine Bjørndal, Estrid Høgdall, Stine Rosenkilde Larsen, Daiva Erentaite, Caroline Holkmann Olsen, Benedicte Parm Ulhøi, Sarah Linéa von Holstein, Irene Wessel, Steffen Heegaard, Preben Homøe
Adenoid cystic carcinoma is among the most frequent malignancies in the salivary and lacrimal glands and has a grave prognosis characterized by frequent local recurrences, distant metastases, and tumor-related mortality. Conversely, adenoid cystic carcinoma of the breast is a rare type of triple-negative (estrogen and progesterone receptor, HER2) and basal-like carcinoma, which in contrast to other triple-negative and basal-like breast carcinomas has a very favorable prognosis. Irrespective of site, adenoid cystic carcinoma is characterized by gene fusions involving MYB, MYBL1, and NFIB, and the reason for the different clinical outcomes is unknown...
February 21, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29467478/reappraisal-of-her2-status-in-the-spectrum-of-advanced-urothelial-carcinoma-a-need-of-guidelines-for-treatment-eligibility
#14
Anissa Moktefi, Damien Pouessel, Jing Liu, Nanor Sirab, Pascale Maille, Pascale Soyeux, Christiane Copie Bergman, Marie Luce Auriault, Dimitri Vordos, Alexandre de la Taille, Stéphane Culine, Yves Allory
Although human epidermal growth factor receptor 2 (HER2) may represent a therapeutic target, its evaluation in urothelial carcinoma of the bladder does not rely on a standardized scoring system by immunohistochemistry or fluorescent in situ hybridization (FISH), as reflected by various methodology in the literature and clinical trials. Our aim was to improve and standardize HER2 amplification detection in bladder cancer. We assessed immunohistochemical criteria derived from 2013 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAPs) guidelines for breast cancer and investigated intratumoral heterogeneity in a retrospective multicentric cohort of 188 patients with locally advanced urothelial carcinoma of the bladder...
February 21, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29466990/targeting-her2-breast-tumors-with-scfv-decorated-bimodal-nanoprobes
#15
Christophe Alric, Katel Hervé-Aubert, Nicolas Aubrey, Souad Melouk, Laurie Lajoie, William Même, Sandra Même, Yann Courbebaisse, Anastasia A Ignatova, Alexey V Feofanov, Igor Chourpa, Emilie Allard-Vannier
BACKGROUND: Recent advances in nanomedicine have shown the great interest of active targeting associated to nanoparticles. Single chain variable fragments (scFv) of disease-specific antibodies are very promising targeting entities because they are small, not immunogenic and able to bind their specific antigens. The present paper is devoted to biological properties in vitro and in vivo of fluorescent and pegylated iron oxide nanoparticles (SPIONs-Cy-PEG-scFv) functionalized with scFv targeting Human Epithelial growth Receptor 2 (HER2)...
February 21, 2018: Journal of Nanobiotechnology
https://www.readbyqxmd.com/read/29465777/expression-of-mage-a-and-ny-eso-1-cancer-testis-antigens-is-enriched-in-triple-negative-invasive-breast-cancers
#16
Ashwini Raghavendra, Priyakshi Kalita-de Croft, Ana Cristina Vargas, Chanel E Smart, Peter T Simpson, Jodi M Saunus, Sunil R Lakhani
AIMS: A better understanding of the expression of cancer testis antigens (CTA) in breast cancer might identify new immunotherapy options, especially for triple-negative (TN) tumours, which lack expression of conventional therapeutic targets ER, PR and HER2 (receptors for Oestrogen, Progesterone and Human epidermal growth factor). The aim of this study was to quantify the expression of MAGE-A and NY-ESO-1 CTAs in breast cancer, and relate this to known clinicopathologic parameters. METHODS AND RESULTS: We surveyed MAGE-A and NY-ESO-1 protein expression in an unselected cohort of 367 breast tumours (out of which 65 tumours were TN), with accompanying clinical follow-up data, using immunohistochemistry (IHC) analysis of tissue microarrays...
February 21, 2018: Histopathology
https://www.readbyqxmd.com/read/29464534/a-hedgehog-pathway-dependent-gene-signature-is-associated-with-poor-clinical-outcomes-in-luminal-a-breast-cancer
#17
M Rudolph, S T Sizemore, Y Lu, K Y Teng, M M Basree, R Reinbolt, C D Timmers, G Leone, M C Ostrowski, S Majumder, B Ramaswamy
PURPOSE: High expression of glioma-associated oncogene homolog-1 (GLI1) is associated with poor prognosis in estrogen receptor (ER) positive breast cancers. We sought to define a GLI1-dependent gene signature in ER-positive tumors that could further stratify patients at higher risk for disease recurrence and potentially lead to novel combination therapies. METHODS: We identified an inverse correlation between GLI1 expression and distant disease-free survival (DFS) using a dataset developed at MD Anderson Cancer Center (Hatzis dataset) containing clinical data from 508 breast cancer patients...
February 20, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29464445/night-shift-work-and-breast-cancer-a-pooled-analysis-of-population-based-case-control-studies-with-complete-work-history
#18
Emilie Cordina-Duverger, Florence Menegaux, Alexandru Popa, Sylvia Rabstein, Volker Harth, Beate Pesch, Thomas Brüning, Lin Fritschi, Deborah C Glass, Jane S Heyworth, Thomas C Erren, Gemma Castaño-Vinyals, Kyriaki Papantoniou, Ana Espinosa, Manolis Kogevinas, Anne Grundy, John J Spinelli, Kristan J Aronson, Pascal Guénel
Night shift work has been suspected to increase breast cancer risk but epidemiological studies have been inconsistent due to heterogeneous assessment of exposure to night work. To overcome this limitation, we pooled data of five population-based case-control studies from Australia, Canada, France, Germany, and Spain into a single harmonized dataset using a common definition of night work including 6093 breast cancer cases and 6933 population controls. The odds ratio for breast cancer in women who ever worked at night for at least 3 h between midnight and 5 a...
February 20, 2018: European Journal of Epidemiology
https://www.readbyqxmd.com/read/29464058/type-iib-dna-topoisomerase-is-downregulated-by-trastuzumab-and-doxorubicin-to-synergize-cardiotoxicity
#19
Jiangsong Jiang, Nishant Mohan, Yukinori Endo, Yi Shen, Wen Jin Wu
Despite heightened risk of cardiotoxicity associated with combination therapy of anthracyclines and trastuzumab in HER2-positive breast cancer patients, little research effort has been invested in exploring the molecular mechanisms of cardiotoxicity induced by this combination therapy. In this study, we demonstrate that trastuzumab downregulates both gene and protein expressions of type IIB DNA topoisomerase/DNA topoisomerase IIB (TOP2B), a major intracellular target mediating doxorubicin-induced cardiotoxicity, in human primary cardiomyocytes...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29464036/breast-cancer-stem-cells-in-her2-negative-breast-cancer-cells-contribute-to-her2-mediated-radioresistance-and-molecular-subtype-conversion-clinical-implications-for-serum-her2-in-recurrent-her2-negative-breast-cancer
#20
Yun Gyoung Kim, Yi Na Yoon, Hyang Suk Choi, Ji-Hyun Kim, Hyesil Seol, Jin Kyung Lee, Min-Ki Seong, In Chul Park, Kwang Il Kim, Hyun-Ah Kim, Jae-Sung Kim, Woo Chul Noh
Although it has been proposed that the beneficial effect of HER2-targeted therapy in HER2-negative breast cancer is associated with the molecular subtype conversion, the underlying mechanism and the clinical biomarkers are unclear. Our study showed that breast cancer stem cells (BCSCs) mediated HER2 subtype conversion and radioresistance in HER2-negative breast cancer cells and evaluated serum HER2 as a clinical biomarker for HER2 subtype conversion. We found that the CD44+ /CD24-/low BCSCs from HER2-negative breast cancer MCF7 cells overexpressed HER2 and EGFR and showed the radioresistant phenotype...
January 19, 2018: Oncotarget
keyword
keyword
5319
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"